We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

73 hedge funds and large institutions have $146M invested in Adamas Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more capital invested

Capital invested by funds: $62M → $146M (+$83.8M)

73% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 11

53% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 17

20% more call options, than puts

Call options by funds: $830K | Put options by funds: $689K

12% more funds holding

Funds holding: 65 → 73 (+8)

Holders
73
Holders Change
+8
Holders Change %
+12.31%
% of All Funds
1.28%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
19
Increased
26
Reduced
17
Closed
11
Calls
$830K
Puts
$689K
Net Calls
+$141K
Net Calls Change
+$191K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$26.8M
2
SCM
Stonepine Capital Management
Oregon
+$13.6M
3
APM
Avidity Partners Management
Texas
+$11.5M
4
Swedbank
Swedbank
Sweden
+$7.75M
5
ACM
AIGH Capital Management
Maryland
+$6.97M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$4.01M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.66M
3
Deutsche Bank
Deutsche Bank
Germany
-$1.66M
4
DAM
Deltec Asset Management
New York
-$1.23M
5
EIM
Essex Investment Management
Massachusetts
-$1.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$24.6M +$26.8M +5,130,723 New
AC
2
Armistice Capital
New York
$18.5M +$5.82M +1,114,000 +41%
SCM
3
Stonepine Capital Management
Oregon
$16.4M +$13.6M +2,609,848 +323%
ACM
4
AIGH Capital Management
Maryland
$10.6M +$6.97M +1,334,892 +152%
APM
5
Avidity Partners Management
Texas
$10.6M +$11.5M +2,200,200 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$8.24M +$3.88M +743,872 +76%
OM
7
Opaleye Management
Massachusetts
$8.02M +$955K +182,800 +12%
Swedbank
8
Swedbank
Sweden
$7.13M +$7.75M +1,485,000 New
Renaissance Technologies
9
Renaissance Technologies
New York
$3.9M -$449K -85,972 -10%
CCPM
10
Cooper Creek Partners Management
New York
$3.84M +$4.18M +800,100 New
BlackRock
11
BlackRock
New York
$2.63M +$73.6K +14,097 +3%
WVP
12
Worth Venture Partners
New Jersey
$2.58M +$1.64M +313,289 +139%
SCM
13
Silverarc Capital Management
Massachusetts
$2.51M +$426K +81,634 +19%
Two Sigma Advisers
14
Two Sigma Advisers
New York
$2.29M +$1.62M +310,600 +185%
ACM
15
Altium Capital Management
New York
$2.16M +$2.35M +450,000 New
Two Sigma Investments
16
Two Sigma Investments
New York
$2.05M +$1.32M +252,924 +145%
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$1.72M -$1.66M -318,234 -47%
Morgan Stanley
18
Morgan Stanley
New York
$1.63M -$4.01M -768,511 -69%
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$1.48M +$316K +60,422 +24%
Jacobs Levy Equity Management
20
Jacobs Levy Equity Management
New Jersey
$1.44M +$410K +78,456 +35%
MIM
21
Monashee Investment Management
Massachusetts
$1.44M +$1.57M +300,000 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$1.38M +$680K +130,162 +82%
MS
23
Maven Securities
Jersey
$1.23M +$1.31M +250,000 New
BCM
24
Bridgeway Capital Management
Texas
$864K +$261K +50,000 +38%
Bank of Montreal
25
Bank of Montreal
Ontario, Canada
$808K +$29.1K +5,580 +3%
1
2 3 4

ADMS Hedge Fund Activity: Q1 2021 in Review

73 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q1 2021, worth a combined $146M — up 135% from $62M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ADMS positions and 11 closed out — a net gain of 8 holders — while 26 added to existing stakes and 17 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $26.8M. The largest seller was Morgan Stanley, cutting an estimated $4.01M.

  • 73 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q1 2021, up from 65 in Q4 2020.
  • Funds reported $146M of Adamas Pharmaceuticals stock for Q1 2021, up 135% quarter-over-quarter.
  • 19 funds opened new Adamas Pharmaceuticals positions in Q1 2021 and 11 closed out, a net change of +8 holders.
  • The largest Adamas Pharmaceuticals buyer in Q1 2021 was Fidelity Investments, an estimated $26.8M added.
  • The largest Adamas Pharmaceuticals seller in Q1 2021 was Morgan Stanley, an estimated $4.01M sold.

Based on aggregated 13F filings for Q1 2021.